Instinct Bio Plans First Genrêver Clinic in Jakarta

NEW YORK and TOKYO, Sept. 4, 2026 (GLOBE NEWSWIRE), Instinct Bio Technical Company Holdings Inc. (Nasdaq: BIOT), a biotechnology firm focused on regenerative medicine and wellness-related technologies, has provided an operational update on its expansion plans and product development initiatives in Indonesia.

The company has made significant progress in its plans to establish a first Genrêver Clinic in Jakarta. It has secured a 213 square meter premises in the Gandaria district and has begun interior construction. The clinic is expected to open by the end of December 2026, pending completion of construction, necessary permits, and operational readiness.

Instinct Bio has also outlined subscription pricing tiers for the Jakarta clinic. The monthly rates are set at $400, $1,000, and $3,000 per customer. Treatment availability will depend on membership terms, physician assessment, scheduling capacity, and regulatory requirements.

In other developments, the company and Invitrx Therapeutics, Inc., have identified an initial product line for potential manufacture in the United States. These products are targeted to begin production in 2026, subject to final formulation, manufacturing scheduling, regulatory considerations, and related commercial arrangements.

Additionally, Instinct Bio and PT Parva CandeLA have identified two initial cosmetic product candidates for the Indonesian market under the Genrêver and Hakua brands. The products include a premium UV cream and a moisturizing gel featuring low-molecular-weight hyaluronic acid technology. Production is expected to commence in 2026, contingent upon product development, regulatory compliance, and manufacturing readiness.

According to Tomoki Nagano, Chief Executive Officer of Instinct Bio, "Over the past few weeks, we have made substantial progress in site development activities in Jakarta and continued discussions with our manufacturing partners in the United States and Indonesia."

Further details about the Genrêver Clinic, subscription structure, and the product candidates can be found in the News & IR section of Instinct Bio's website at https://instinct-biot.com/news.

The company cautions readers that forward-looking statements in this press release, including expectations for clinic openings, subscription offerings, product development, and manufacturing timelines, are subject to risks and uncertainties. Actual results may vary significantly.